DGAP-News
547
0 Kommentare
Biotest AG: Biotest AG: Annual general meeting approves increase of dividend
547 
0 KommentareDGAP-News: Biotest AG / Key word(s): AGM/EGM
Biotest AG: Biotest AG: Annual general meeting approves increase of
dividend
08.05.2013 / 17:04
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG: Annual general meeting approves increase of dividend
- Distribution of EUR 0.50 per ordinary share and EUR 0.56 per preference
share
Dreieich / Frankfurt a. M., 8 May 2013. At the annual general meeting (AGM)
held on 8 May 2013 in Frankfurt am Main shareholders of Biotest AG approved
payment of an increased dividend. With 82,4 percent of the ordinary share
capital represented at the meeting, a payment of EUR 0.50 per ordinary
share and EUR 0.56 per preference share met with wide endorsement. This
equates to a dividend increase of 13.6% relative to last year for ordinary
shares and 12.0% for preference shares. The overall distribution will
amount to EUR 6.2 million.
The annual general meeting attended by around 180 shareholders and guests
also formally discharged the members of the Management and Supervisory
Boards for financial year 2012 and endorsed all of the other agenda items
by a large majority.
The full text of the address given by Professor Gregor Schulz at the AGM is
available at: http://www.biotest.de/ww/de/pub/investor_relations/
hauptversammlung.cfm.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
08.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
210451 08.05.2013
PRESS RELEASE
Biotest AG: Annual general meeting approves increase of dividend
- Distribution of EUR 0.50 per ordinary share and EUR 0.56 per preference
share
Dreieich / Frankfurt a. M., 8 May 2013. At the annual general meeting (AGM)
held on 8 May 2013 in Frankfurt am Main shareholders of Biotest AG approved
payment of an increased dividend. With 82,4 percent of the ordinary share
capital represented at the meeting, a payment of EUR 0.50 per ordinary
share and EUR 0.56 per preference share met with wide endorsement. This
equates to a dividend increase of 13.6% relative to last year for ordinary
shares and 12.0% for preference shares. The overall distribution will
amount to EUR 6.2 million.
The annual general meeting attended by around 180 shareholders and guests
also formally discharged the members of the Management and Supervisory
Boards for financial year 2012 and endorsed all of the other agenda items
by a large majority.
The full text of the address given by Professor Gregor Schulz at the AGM is
available at: http://www.biotest.de/ww/de/pub/investor_relations/
hauptversammlung.cfm.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
08.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
210451 08.05.2013
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Artikel zu den Werten
Auch bei Lesern beliebt
